PBS updates

Imfinzi (Durvalumab)

durvalumab 120 mg/2.4 mL injection, 2.4 mL vial · INJECTION · PBS code 11915D

STREAMLINED

• • First listed on the PBS: 2020-03-01.
• • Repeats: 4.
• • PBS program: IP.

Eligibility criteria for subsidised access

The following is the government's own wording from the PBS Schedule, shown unchanged.

Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1

Unresectable Stage III non-small cell lung cancer

Initial treatment

Patient must have received platinum based chemoradiation therapy; AND

The condition must not have progressed following platinum based chemoradiation therapy; AND

Patient must have a WHO performance status of 0 or 1; AND

Patient must be untreated with immunotherapy at commencement of this drug; AND

The treatment must be the sole PBS-subsidised systemic anti-cancer therapy for this condition.

Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1

Unresectable Stage III non-small cell lung cancer

Continuing treatment

Patient must have previously received PBS-subsidised treatment with this drug for this condition; AND

Patient must not have developed disease progression while being treated with this drug for this condition; AND

The treatment must be the sole PBS-subsidised systemic anti-cancer therapy for this condition; AND

The treatment must not exceed 12 months in total for this condition under the initial and continuing restriction combined; AND

The treatment must be once in a lifetime with this drug for this condition.

Not medical advice. Voxsanity republishes public PBS data in plain English. PBS listing status and criteria can change; always confirm current subsidised availability with your doctor or pharmacist.

Source: Pharmaceutical Benefits Scheme (PBS), © Commonwealth of Australia. Data used and redistributed under permission; not modified from its original wording where displayed verbatim.